It is associated with many cellular targets (i.e., NF-κB, JAKs/STATs, MAPKs, TNF-γ, IL-6, PPARγ, and TRPV1) that effectively reduce the progression of IBD with promising results [22,23,24,25,26,27]. Here, NFKB1 is linked to inflammatory bowel disease.